Published in Nat Commun on May 29, 2014
RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. Cancer Cell (2015) 4.30
Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell (2014) 4.17
Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell (2015) 2.39
Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies. Cancer Cell (2015) 1.70
TANRIC: An Interactive Open Platform to Explore the Function of lncRNAs in Cancer. Cancer Res (2015) 1.36
Systematic pan-cancer analysis of tumour purity. Nat Commun (2015) 1.35
A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clin Cancer Res (2015) 1.12
Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clin Cancer Res (2015) 1.09
Inferring causal molecular networks: empirical assessment through a community-based effort. Nat Methods (2016) 1.04
The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers. Oncogene (2015) 1.01
Integrated genomic and molecular characterization of cervical cancer. Nature (2017) 0.96
Influence of biospecimen variables on proteomic biomarkers in breast cancer. Clin Cancer Res (2014) 0.93
Generating a focused view of disease ontology cancer terms for pan-cancer data integration and analysis. Database (Oxford) (2015) 0.92
The PI3K/AKT Pathway and Renal Cell Carcinoma. J Genet Genomics (2015) 0.90
Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. Oncogene (2015) 0.88
Predicting cancer prognosis using functional genomics data sets. Cancer Inform (2014) 0.88
The microRNA-200/Zeb1 axis regulates ECM-dependent β1-integrin/FAK signaling, cancer cell invasion and metastasis through CRKL. Sci Rep (2016) 0.85
Metabolic/Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome. Sci Rep (2016) 0.84
Bioinformatics Mining and Modeling Methods for the Identification of Disease Mechanisms in Neurodegenerative Disorders. Int J Mol Sci (2015) 0.83
Glioblastoma-derived Macrophage Colony-stimulating Factor (MCSF) Induces Microglial Release of Insulin-like Growth Factor-binding Protein 1 (IGFBP1) to Promote Angiogenesis. J Biol Chem (2015) 0.82
ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis. Oncogene (2016) 0.81
Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts. Mol Cancer Res (2015) 0.81
Rab25 acts as an oncogene in luminal B breast cancer and is causally associated with Snail driven EMT. Oncotarget (2016) 0.81
Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer. Clin Cancer Res (2015) 0.81
Integrative DNA methylome analysis of pan-cancer biomarkers in cancer discordant monozygotic twin-pairs. Clin Epigenetics (2016) 0.80
Linking patient outcome to high throughput protein expression data identifies novel regulators of colorectal adenocarcinoma aggressiveness. F1000Res (2015) 0.80
MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer. Clin Cancer Res (2015) 0.79
Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p. Oncogene (2016) 0.79
Analysis of Reverse Phase Protein Array Data: From Experimental Design towards Targeted Biomarker Discovery. Microarrays (Basel) (2015) 0.78
Development of a robust classifier for quality control of reverse-phase protein arrays. Bioinformatics (2014) 0.78
Human Proteomic Variation Revealed by Combining RNA-Seq Proteogenomics and Global Post-Translational Modification (G-PTM) Search Strategy. J Proteome Res (2016) 0.78
Ubenimex attenuates acquired sorafenib resistance in renal cell carcinoma by inhibiting Akt signaling in a lipophagy associated mechanism. Oncotarget (2016) 0.77
Molecular portraits: the evolution of the concept of transcriptome-based cancer signatures. Brief Bioinform (2015) 0.77
A bead-based western for high-throughput cellular signal transduction analyses. Nat Commun (2016) 0.77
Validation of SCT Methylation as a Hallmark Biomarker for Lung Cancers. J Thorac Oncol (2015) 0.77
The reverse control of irreversible biological processes. Wiley Interdiscip Rev Syst Biol Med (2016) 0.77
A Multi-Method Approach for Proteomic Network Inference in 11 Human Cancers. PLoS Comput Biol (2016) 0.77
Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer. Semin Oncol (2016) 0.77
Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes. Cancer Metab (2016) 0.77
Clinical proteomics: promises, challenges and limitations of affinity arrays. Proteomics Clin Appl (2015) 0.77
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell (2017) 0.76
High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype. Clin Cancer Res (2016) 0.76
Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer. Clin Cancer Res (2015) 0.76
Advancement of mass spectrometry-based proteomics technologies to explore triple negative breast cancer. Mol Biosyst (2016) 0.76
p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status. Leukemia (2016) 0.76
Non-mutational (epigenomic) structural variation in the transcriptome of cancer cells. Oncotarget (2015) 0.75
Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling. Cell Syst (2016) 0.75
Confronting the Care Delivery Challenges Arising from Precision Medicine. Front Oncol (2016) 0.75
A pan-cancer analysis of prognostic genes. PeerJ (2016) 0.75
Overlap of the cancer genome atlas and the immune epitope database. Oncol Lett (2016) 0.75
An integrative and comparative study of pan-cancer transcriptomes reveals distinct cancer common and specific signatures. Sci Rep (2016) 0.75
Reverse phase protein arrays in signaling pathways: a data integration perspective. Drug Des Devel Ther (2015) 0.75
Integrated RNA-seq and DNase-seq analyses identify phenotype-specific BMP4 signaling in breast cancer. BMC Genomics (2017) 0.75
Androgen receptor as potential therapeutic target in metastatic endometrial cancer. Oncotarget (2016) 0.75
Inferring RBP-Mediated Regulation in Lung Squamous Cell Carcinoma. PLoS One (2016) 0.75
The NF1 somatic mutational landscape in sporadic human cancers. Hum Genomics (2017) 0.75
Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer. Oncol Lett (2017) 0.75
Improving Cancer Gene Expression Data Quality through a TCGA Data-Driven Evaluation of Identifier Filtering. Cancer Inform (2015) 0.75
An Atlas of the Human Kinome Reveals the Mutational Landscape Underlying Dysregulated Phosphorylation Cascades in Cancer. Cancer Res (2016) 0.75
Functional proteomic characterization of cancer cell lines. Oncoscience (2017) 0.75
Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers. Genome Res (2017) 0.75
The 150 most important questions in cancer research and clinical oncology series: questions 57-66 : Edited by Chinese Journal of Cancer. Chin J Cancer (2017) 0.75
Recent advances in methods to assess the activity of the kinome. F1000Res (2017) 0.75
Pan-urologic cancer genomic subtypes that transcend tissue of origin. Nat Commun (2017) 0.75
Epigenetic Regulation of KPC1 Ubiquitin Ligase Effects the NF-κB Pathway in Melanoma. Clin Cancer Res (2017) 0.75
Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening. BMC Genomics (2017) 0.75
Molecular heterogeneity at the network level: high-dimensional testing, clustering and a TCGA case study. Bioinformatics (2017) 0.75
How Ribosomes Translate Cancer. Cancer Discov (2017) 0.75
An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors. Clin Proteomics (2017) 0.75
Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A (1998) 192.97
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 34.13
mTOR signaling in growth control and disease. Cell (2012) 29.21
Sparse inverse covariance estimation with the graphical lasso. Biostatistics (2007) 24.38
Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature (2013) 13.60
Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature (2006) 12.13
Towards a knowledge-based Human Protein Atlas. Nat Biotechnol (2010) 11.05
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87
Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell (2005) 7.75
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov (2011) 4.78
HER-2 testing in breast cancer using parallel tissue-based methods. JAMA (2004) 4.60
Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther (2007) 3.84
Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell (2009) 3.36
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics (2010) 3.25
Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun (2013) 2.94
Overexpression of focal adhesion kinase in head and neck squamous cell carcinoma is independent of fak gene copy number. Clin Cancer Res (2006) 2.75
Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol (2013) 2.61
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov (2012) 2.61
Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist (2013) 2.55
High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol (2002) 2.33
Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2009) 2.32
The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol (2006) 2.18
Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal (2009) 2.11
Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res (2013) 2.09
Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res (2012) 1.95
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med (2012) 1.85
Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A (2010) 1.83
VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst (2002) 1.75
Variable slope normalization of reverse phase protein arrays. Bioinformatics (2009) 1.66
TCPA: a resource for cancer functional proteomics data. Nat Methods (2013) 1.64
HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res (2008) 1.63
Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases. Am J Clin Pathol (2010) 1.62
Predictive markers in breast cancer--the present. Histopathology (2008) 1.62
Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther (2010) 1.62
Markers for individualised therapy in endometrial carcinoma. Lancet Oncol (2012) 1.61
The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res (2012) 1.54
Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res (2011) 1.32
Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol (2004) 1.28
Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol (2011) 1.24
Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer. Clin Med Insights Oncol (2013) 1.19
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest (2013) 1.16
Integrated gene copy number and expression microarray analysis of gastric cancer highlights potential target genes. Int J Cancer (2008) 1.07
Systematic review of HER2 breast cancer testing. Appl Immunohistochem Mol Morphol (2009) 1.04
Molecular profiling of colon tumors: the search for clinically relevant biomarkers of progression, prognosis, therapeutics, and predisposition. Ann Surg Oncol (2011) 1.02
No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas. Pathol Oncol Res (2008) 1.02
Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins. Mol Oncol (2013) 0.97
Clinical significance of E-cadherin, β-catenin, vimentin and S100A4 expression in completely resected squamous cell lung carcinoma. J Clin Pathol (2013) 0.97
Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. Mol Med (2013) 0.90
Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung. Mod Pathol (2012) 0.90
Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung. J Clin Pathol (2005) 0.88
Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians. Tumour Biol (2013) 0.84